A close examination of BeiGene’s (NASDAQ: BGNE; HKG: 6160; SHA: 688235) recent annual report has revealed that the company has terminated its earlier partnership with US biotech firm Shoreline Therapeutics Inc. The agreement, which was set to be effective from the first quarter of 2024, did not provide a specific reason for the dissolution of the partnership.
BeiGene initially joined forces with Shoreline in June 2021, securing a partnership with an upfront payment of USD 45 million. The collaboration was aimed at researching and developing a suite of natural killer (NK)-based cell therapies leveraging Shoreline’s proprietary induced pluripotent stem cell (iPSC) NK cell technology. The termination of this partnership marks the end of a significant endeavor in the field of cellular therapies.- Flcube.com
